Header Logo

Connection

Matthew Meriggioli to Female

Back to Details
This is a "connection" page, showing publications Matthew Meriggioli has written about Female.
Matthew Meriggioli
Connection Strength
0.421
Female
  1. The Clinical Spectrum of Necrotizing Autoimmune Myopathy: A Mixed Bag With Blurred Lines. JAMA Neurol. 2015 Sep; 72(9):977-9.
    View in: PubMed
    Score: 0.038
  2. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun. 2014 Aug; 52:64-73.
    View in: PubMed
    Score: 0.034
  3. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol. 2012 Dec; 145(3):209-23.
    View in: PubMed
    Score: 0.031
  4. GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol. 2011 Dec 15; 240-241:65-73.
    View in: PubMed
    Score: 0.029
  5. In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor. Exp Neurol. 2010 Oct; 225(2):320-7.
    View in: PubMed
    Score: 0.027
  6. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve. 2009 Aug; 40(2):279-86.
    View in: PubMed
    Score: 0.025
  7. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009 May; 8(5):475-90.
    View in: PubMed
    Score: 0.024
  8. Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve. 2006 Nov; 34(5):666-9.
    View in: PubMed
    Score: 0.021
  9. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006 Apr 25; 66(8):1245-7.
    View in: PubMed
    Score: 0.020
  10. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25; 61(10):1438-40.
    View in: PubMed
    Score: 0.017
  11. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep; 998:494-9.
    View in: PubMed
    Score: 0.016
  12. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021 07 01; 78(7):834-841.
    View in: PubMed
    Score: 0.014
  13. Myasthenia gravis. Clin Neuropharmacol. 2000 Nov-Dec; 23(6):291-5.
    View in: PubMed
    Score: 0.014
  14. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve. 2000 Aug; 23(8):1287-9.
    View in: PubMed
    Score: 0.013
  15. Distinguishing clinical and electrodiagnostic features of X-linked bulbospinal neuronopathy. Muscle Nerve. 1999 Dec; 22(12):1693-7.
    View in: PubMed
    Score: 0.013
  16. Conduction block and continuous motor unit activity in chronic acquired demyelinating polyneuropathy. Muscle Nerve. 1999 Apr; 22(4):532-7.
    View in: PubMed
    Score: 0.012
  17. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm. 2019 01; 6(1):e523.
    View in: PubMed
    Score: 0.012
  18. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018 12; 17(12):1043-1052.
    View in: PubMed
    Score: 0.012
  19. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173.
    View in: PubMed
    Score: 0.010
  20. Novel and recurrent EMD mutations in patients with Emery-Dreifuss muscular dystrophy, identify exon 2 as a mutation hot spot. J Hum Genet. 2011 Aug; 56(8):589-94.
    View in: PubMed
    Score: 0.007
  21. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord. 2006 Feb; 16(2):137-43.
    View in: PubMed
    Score: 0.005
  22. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun. 2005 May; 24(3):261-8.
    View in: PubMed
    Score: 0.005
  23. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28; 63(12):2390-2.
    View in: PubMed
    Score: 0.005
  24. [Can the treatment with L-carnitine improve the inflammation in chronic hemodialysis patients?]. G Ital Nefrol. 2004 Nov-Dec; 21 Suppl 30:S204-7.
    View in: PubMed
    Score: 0.004
  25. Prominent inflammatory changes on muscle biopsy in patients with Miyoshi myopathy. Neuromuscul Disord. 1999 Oct; 9(6-7):417-20.
    View in: PubMed
    Score: 0.003
  26. Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin. Minerva Med. 1998 Nov-Dec; 89(11-12):405-9.
    View in: PubMed
    Score: 0.003
  27. Circulating levels of IGF-I in patients with chronic uremia on conservative dietary treatment. Ren Fail. 1998 Mar; 20(2):357-60.
    View in: PubMed
    Score: 0.003
  28. Coagulation activation in extracorporeal hemodialysis. Int J Artif Organs. 1997 Mar; 20(3):163-5.
    View in: PubMed
    Score: 0.003
  29. [Coagulation in hemodialysis]. Minerva Med. 1996 Nov; 87(11):509-14.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.